Suraksha Diagnostics Reports 17% Revenue Growth, Expands Genomics Division
Suraksha Diagnostic, Eastern India's largest integrated diagnostic chain, reported a 17% year-over-year revenue growth for Q2 FY26, reaching ₹795.80 crore. The company's EBITDA increased by 1.9% to ₹249.66 crore, while PAT decreased by 13.1% to ₹88.28 crore. The EBITDA margin declined by 500 bps to 31.7%. Suraksha added 11 new centers in H1 FY26 and plans to open 9 more in H2. The company launched Suraksha Genomics in July 2025 for advanced genetic testing and acquired a 63% stake in Fetomat Wellness in April 2025. Management remains optimistic about future growth and profitability as new centers mature.
*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic , the largest integrated diagnostic chain in Eastern India, has reported a robust 17% year-over-year revenue growth for the second quarter of fiscal year 2026. The company's strategic expansion and focus on advanced diagnostic services have contributed to its strong performance.
Financial Highlights
Suraksha Diagnostics demonstrated solid financial results for Q2 FY26:
| Metric | Q2 FY26 | Q2 FY25 | YoY Change |
|---|---|---|---|
| Revenue | ₹795.80 | ₹680.67 | +16.9% |
| EBITDA | ₹249.66 | ₹245.07 | +1.9% |
| EBITDA Margin | 31.7% | 36.7% | -500 bps |
| PAT | ₹88.28 | ₹101.56 | -13.1% |
The company's revenue growth was primarily driven by an increase in test volumes. However, the EBITDA margin experienced a decline due to the impact of new center openings, which are yet to reach maturity.
Operational Expansion
Suraksha Diagnostics has been actively expanding its network:
- Added 11 new centers in H1 FY26
- Plans to open 3 hub centers and 6 spoke centers in H2 FY26
- Total planned additions for FY26: 20 centers
Strategic Initiatives
Launch of Suraksha Genomics
In July 2025, Suraksha Diagnostics launched Suraksha Genomics, a dedicated vertical for advanced genetic and molecular testing services. This strategic move positions the company to capitalize on the growing genomics market, which is projected to reach $186.64 billion globally by 2035.
Suraksha Genomics offers:
- Prenatal diagnostics
- Inherited disease analysis
- Pharmacogenomics
- Oncology-focused molecular panels
The company aims to expand into high-impact domains such as whole genome and metagenomic testing, AI integration, and population-scale genomic screening initiatives.
Acquisition of Fetomat Wellness
In April 2025, Suraksha Diagnostics acquired a 63% stake in Fetomat Wellness Private Limited, a network of fertility and pregnancy care clinics. This acquisition enhances Suraksha's offerings in fetal and maternal medicine, further strengthening its position in the diagnostics sector.
Management Commentary
Mrs. Ritu Mittal, Joint Managing Director & CEO, commented on the results: "Suraksha reported another quarter of strong top-line growth, driven primarily by test volumes. The QoQ and YoY total revenue growth was 8.3% and 16.9%, respectively."
She added, "As the new centers mature, their margin contributions will increase, moving overall performance closer to industry benchmarks and supporting improved profitability across our network. We remain committed to creating value for our shareholders, driven by innovation, operational excellence and sustainable growth."
Future Outlook
Suraksha Diagnostics is well-positioned for future growth, leveraging its expanded network, advanced genomics capabilities, and strategic acquisitions. The company's focus on innovation and operational excellence is expected to drive long-term value creation for shareholders in the competitive Indian diagnostics market.
